TECLens Closes $10 Million Series A2 Extension Financing to Advance Proof-of-Concept Study for Non-Invasive Vision Correction Technology
Series A2 financing supports continued expansion of first-in-human clinical program for the company’s proprietary qCXL™ platform STAMFORD, Connecticut – August 25, 2026 – TECLens, Inc., a clinical-stage ophthalmic medical device company pioneering non-invasive vision correction, today announced the closing of a $10 million Series A2 extension financing. The round includes participation from existing investors, including Johnson & Johnson (through […]